Fate Therapeutics Inc. – Material Contracts Watch

from 10-Q 4 pages Fate Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-Q 5 pages Fate Therapeutics, Inc. Severance and Change in Control Policy Adopted Effective January 14, 2018 Amended on May 27, 2025

from 8-K 7 pages Fate Therapeutics, Inc. (“FATE” or the “Company”) Is Pleased to Offer You an Exempt Full-Time Position as Chief Financial Officer, Reporting to the Company’s President & Chief Executive Officer. This Position Has an Anticipated Start Date of October 20, 2025 (“Start Date”), and Requires That You Provide Full-Time Services at the Company’s Corporate Headquarters in San Diego, California During the Company’s Business Days of Operation. Additional Information Is Outlined Below. Compensation & Benefits as an Exempt Employee, You Will Be Paid an Initial Annualized Base Salary of $495,000. This Salary Will Be Paid, Less Applicable State and Federal Taxes and Withholdings, in Accordance With Our Standard Payroll Practices, Which Currently Is Every Two Weeks

from 10-Q 6 pages Amendment No. 5 to Collaboration and Option Agreement

from 8-K 54 pages Fate Therapeutics, Inc. Second Amended and Restated 2022 Stock Option and Incentive Plan

from 10-K 13 pages Employment Agreement 1

from 10-K 4 pages Fate Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 8-K 9 pages Strategic Advisory Services Agreement

from 10-Q 5 pages Amendment No. 4 to Collaboration and Option Agreement

from 8-K 16 pages Fate Therapeutics, Inc. [Amended and Restated]1 [Director][officer] Indemnification Agreement

from 8-K 17 pages Fate Therapeutics, Inc. Amended and Restated 2022 Stock Option and Incentive Plan

from 8-K 17 pages Securities Purchase Agreement

from 10-K 21 pages Exclusive License Agreement Re: Bcm Blg #[***], Entitled “Chimeric Defense Receptors (Cdrs) for the Selective Targeting of Pathogenic T Cells”

from 10-K 4 pages Amendment No. 3 to Collaboration and Option Agreement

from 10-Q 4 pages Fate Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 8-K 3 pages Ono Pharmaceutical Co., Ltd. 8-2, Kyutaromachi 1-Chome, Chuo-Ku, Osaka-Shi 541-8564, Japan Tel : 81-6-6263-5670 Fax : 81-6-6263-2976 November 7, 2022 Fate Therapeutics, Inc. Corporate Headquarters 12278 Scripps Summit Drive San Diego, Ca 92131 United States of America Attention: Mr. Scott Wolchko Re: Amendment to Collaboration and Option Agreement With Respect to Collaboration Candidate 2

from 10-Q 13 pages Amendment 01 to Collaboration and Option Agreement

from 10-K 31 pages License Agreement

from 10-Q 3 pages Fate Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-K 22 pages Patent License Agreement